© 1994

Principles and Treatment of Lipoprotein Disorders

  • Gotthard Schettler
  • Andreas J. R. Habenicht

Part of the Handbook of Experimental Pharmacology book series (HEP, volume 109)

Table of contents

  1. Front Matter
    Pages I-XXIII
  2. Physiology and Pathophysiology of Lipid Metabolism

    1. Front Matter
      Pages 1-1
    2. H. B. Brewer
      Pages 29-51
    3. W. J. S. de Villiers, G. A. Coetzee, D. R. van der Westhuyzen
      Pages 53-87
    4. G. Utermann, H. J. Menzel
      Pages 89-138
    5. A. J. R. Habenicht, P. B. Salbach, U. Janssen-Timmen
      Pages 139-174
    6. T. Olivecrona, G. Olivecrona
      Pages 175-205
    7. D. Kritchevsky
      Pages 207-218
  3. Lipid Lowering Therapy

    1. Front Matter
      Pages 219-219
    2. D. H. Blankenhorn, H. N. Hodis
      Pages 221-245
    3. D. Seidel
      Pages 279-300
  4. Lipid Lowering Drugs

    1. Front Matter
      Pages 301-301
    2. D. R. Illingworth, E. B. Schmidt
      Pages 303-324
    3. A. Gaw, C. J. Packard, J. Shepherd
      Pages 325-348
    4. A. G. Olsson
      Pages 349-400
    5. P. Schwandt, W. O. Richter
      Pages 401-427
    6. J. Davignon
      Pages 429-469
    7. K. J. Lackner, E. von Hodenberg
      Pages 471-492

About this book


Major advances have been made in the understanding of the molecular mechanisms of atherosclerosis, the disease that still affects more than 50 percent of the population in the highly industrialized countries. This volume covers the most recent advances in the treatment of hyperlipidemia. It represents a necessary update because molecular mechanisms of atherogenesis have been discovered in the past few years and their molecular mechanisms of action identified. Extensively treated are the molecular mechanisms of disease etiology of arteriosclerosis in relation to the major risk factor "hyperlipidemia", rationale for more effective treatment of this disease by dietary means, the treatment of associated or causing diseases, and the treatment using hypolipidemic drugs.


Arterienverkalkung Atherogenesis Dietary Intervention Herzkrankheit Hyperlipidemia Hyperlipoproteinämie Lipid Lowering Drugs Lipoprotein arteriosclerosis atherosclerosis cardiovascular disease lipide protein vascular disease

Editors and affiliations

  • Gotthard Schettler
    • 1
  • Andreas J. R. Habenicht
    • 2
  1. 1.Klinisches Institut für Herzinfarktforschung an der Medizinischen UniversitätsklinikUniversity of HeidelbergHeidelbergGermany
  2. 2.School of Medicine, Department of Medicine, Division of Endocrinology and MetabolismUniversity of HeidelbergHeidelbergGermany

Bibliographic information

Industry Sectors
Health & Hospitals
Pharmacology & Toxicology
Consumer Packaged Goods